Secukinumab: Psoriatic Arthritis Patients Show Drug’s Sustained Efficacy

Novartis’ secukinumab, or Cosentyx has been shown in new trial results to be considerably superior to placebo in treatment of psoriatic arthritis. The trial also demonstrated the compound’s continual efficacy over one year in patients suffering from the condition.

The one year results of the Phase III FUTURE 2 Study were published in the journal Lancet.

Secukinumab is the first interleukin-17A or IL-17A inhibitor to show efficacy in a Phase III study in adult patients with active psoriatic arthritis (PsA).

Psoriatic arthritis, also known as arthritis psoriatica, arthropathic psoriasis or psoriatic arthropathy, is a form of inflammatory arthritis that occurs in up to 30 percent of people who have the chronic skin condition psoriasis.

Novartis Pharmaceuticals’ Vasant Narasimhan, Global Head of Development, said:

“Secukinumab is the first IL-17A inhibitor to show consistent efficacy through one year in Psoriatic Arthritis, Psoriasis, and Ankylosing spondylitis. Novartis has recently filed global regulatory submissions for secukinumab in both psoriatic arthritis and ankylosing spondylitis”.

Narasimhan furthermore said that Novartis will continue working to bring this progress in treatment to patients suffering from these debilitating diseases.

American College of Rheumatology response criteria or ACR 20 at Week 24, the primary endpoint of the study, was met by Secukinumab. Response rates were significantly higher in the secukinumab 300 mg and 150 mg groups versus placebo, with clinical improvements observed as early as Week 3.

In FUTURE 1, results of which were announced in late 2014, secukinumab patients had significantly less progression of joint structural damage compared to placebo, as evaluated by erosion and joint narrowing scores.

FUTURE 1 showed the majority of secukinumab patients achieving ACR20 responses at Week 24 also maintained the response at Week 52 with continued treatment; inhibition of joint structural damage was also sustained with secukinumab, in exploratory analyses.

In FUTURE 2, secukinumab was tolerated well, with a safety profile consistent with that observed in the psoriasis clinical trial program involving nearly 5,000 patients.